Borchmann P - Search Results

1

Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP.

Jachimowicz RD, Pieper L, Reinke S, Gontarewicz A, Plütschow A, Haverkamp H, Frauenfeld L, Fend F, Overkamp M, Jochims F, Thorns C, Leo Hansmann M, Möller P, Rosenwald A, Stein H, Reinhardt HC, Borchmann P, von Tresckow B, Engert A, Klapper W. Jachimowicz RD, et al. Among authors: borchmann p. Haematologica. 2021 Jun 1;106(6):1684-1692. doi: 10.3324/haematol.2019.243287. Haematologica. 2021. PMID: 32381573 Free PMC article.

2

Idarubicin: a brief overview on pharmacology and clinical use.

Borchmann P, Hübel K, Schnell R, Engert A. Borchmann P, et al. Int J Clin Pharmacol Ther. 1997 Feb;35(2):80-3. Int J Clin Pharmacol Ther. 1997. PMID: 9147715 Review.

3

A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.

Hübel K, Tesch H, Kröger B, Schnell R, Borchmann P, Diehl V, Engert A. Hübel K, et al. Among authors: borchmann p. Leukemia. 1997 Dec;11 Suppl 5:S47-51. Leukemia. 1997. PMID: 9436939 Clinical Trial.

4

Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.

Schnell R, Vitetta E, Schindler J, Barth S, Winkler U, Borchmann P, Hansmann ML, Diehl V, Ghetie V, Engert A. Schnell R, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Aug;30(5-6):525-37. doi: 10.3109/10428199809057565. Leuk Lymphoma. 1998. PMID: 9711915 Clinical Trial.

5

New drugs in the treatment of Hodgkin's disease.

Borchmann P, Schnell R, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 1998;9 Suppl 5:S103-8. doi: 10.1093/annonc/9.suppl_5.s103. Ann Oncol. 1998. PMID: 9926247 Review.

6

A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A. Schnell R, et al. Among authors: borchmann p. Clin Cancer Res. 2002 Jun;8(6):1779-86. Clin Cancer Res. 2002. PMID: 12060617 Clinical Trial.

7

Current strategies of antibody-based treatment in Hodgkin's disease.

Schnell R, Borchmann P, Schulz H, Engert A. Schnell R, et al. Among authors: borchmann p. Ann Oncol. 2002;13 Suppl 1:57-66. doi: 10.1093/annonc/13.s1.57. Ann Oncol. 2002. PMID: 12078905 Free article. Review.

8

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.

Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A. Borchmann P, et al. Blood. 2003 Nov 15;102(10):3737-42. doi: 10.1182/blood-2003-02-0515. Epub 2003 Jul 24. Blood. 2003. PMID: 12881320 Free article.

9

Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.

Borchmann P, Morschhauser F, Parry A, Schnell R, Harousseau JL, Gisselbrecht C, Rudolph C, Wilhelm M, Günther H, Pfreundschuh DM, Camboni G, Engert A. Borchmann P, et al. Haematologica. 2003 Aug;88(8):888-94. Haematologica. 2003. PMID: 12935976 Clinical Trial.

10

The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5.

Hansen HP, Recke A, Reineke U, Von Tresckow B, Borchmann P, Von Strandmann EP, Lange H, Lemke H, Engert A. Hansen HP, et al. Among authors: borchmann p. FASEB J. 2004 May;18(7):893-5. doi: 10.1096/fj.03-0901fje. Epub 2004 Mar 19. FASEB J. 2004. PMID: 15033921

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

259 results

Search Page

Filters